Cadila Healthcare receives EIR for Dabhasa unit

06 Dec 2019 Evaluate

Cadila Healthcare’s API manufacturing facility located at Dabhasa in Gujarat has received an Establishment Inspection Report (EIR). The USFDA had conducted an inspection at the facility from October 7 to 11, 2019. The EIR report stated that the classification of the facility is ‘No Action Indicated (NAI)’.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

937.80 2.80 (0.30%)
16-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1536.95
Dr. Reddys Lab 6038.00
Cipla 1384.30
Zydus Lifesciences 937.80
Lupin 1613.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.